ZNTL Jan 2025 12.500 put
| Previous Close | 2.7000 |
| Open | N/A |
| Bid | 0.5500 |
| Ask | 5.0000 |
| Strike | 12.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.7000 - 2.7000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GuruFocus.comInsider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
On May 31, 2024, Cam Gallagher, President and Interim Chief Financial Officer of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL), sold 9,597 shares of the company.
GlobeNewswireZentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET. Access to a live webcast of this event,
- GlobeNewswire
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three
